Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab SC in SLE with Active Skin Manifestations
NCT02962960Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Feb 2017; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02962960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962960.